Subscribe
19 September 2017Americas

Video interview: Allen & Overy on the UPC and CRISPR

The Unified Patent Court (UPC) is likely to spark years of uncertainty and may even become part of the UK’s negotiations for Brexit.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Video interview: Allen & Overy on CRISPR evolution
22 September 2017   To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
Video interview: Allen & Overy on CRISPR evolution
22 September 2017   To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.

More on this story

Americas
Video interview: Allen & Overy on CRISPR evolution
22 September 2017   To evaluate how the CRISPR licensing landscape might evolve, parties need to analyse the current patent environment.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York